Company profile
Aclaris Therapeutics, Inc.
NASDAQ:ACRSBiotechnology: Pharmaceutical Preparations
Drug pipeline (5)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Hydrogen peroxide | approved | — | 11 | approved |
| Ifidancitinib | phase2 | — | 5 | no active trials |
| Lepzacitinib | phase2 | — | 1 | no active trials |
| Modzatinib | phase2 | — | 1 | no active trials |
| Zunsemetinib | phase2 | — | 5 | completed, terminated |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (33)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03210337 | phase2 | completed | 2017-08-01 | 2018-03-16 | Aclaris Therapeutics, Inc. | A Phase2 of A-101 Topical Solution in Subjects With Common Warts |
| NCT02667275 | phase3 | completed | 2016-01-01 | 2016-10-01 | Aclaris Therapeutics, Inc. | A Randomized, Double-Blind, Vehicle-Controlled Study in Subjects With Seborrheic Keratosis |
| NCT03148691 | phase2 | completed | 2017-05-17 | 2018-02-28 | Aclaris Therapeutics, Inc. | A Randomized, Vehicle-Controlled Study of 2 Concentrations of A-101 for the Treatment of Seborrheic Keratosis |
| NCT03495817 | phase2 | completed | 2018-03-22 | 2019-10-15 | Aclaris Therapeutics, Inc. | A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution |
| NCT02667236 | phase3 | completed | 2016-01-01 | 2016-10-01 | Aclaris Therapeutics, Inc. | A Study of A-101 Solution 40% in Subjects With Seborrheic Keratosis. |
FDA applications (1)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| NDA 209305 | NDA | ACLARIS THERAPEUTICS INC | ||||
Loading… | ||||||